Lotte Biologics, Abtis collaborate on next-generation ADC technology development

CAR-T Digest - August 2020

11 July 2025: Lotte Biologics, Abtis collaborate on next-generation ADC technology development

Lotte Biologics and Abtis signed an MOU to co-develop next-generation ADC technologies, integrating Abtis’ AbClick linker platform with Lotte’s conjugation production capabilities at its syracuse facility
The partnership supports a one-stop ADC development service, covering manufacturing, clinical trials, and commercial production, leveraging Lotte’s existing SoluFlex Link platform co-developed with Kanaph Therapeutics
Both companies aim to offer differentiated ADC therapies, with a focus on improving drug quality, stability, and patient outcomes through innovative, scalable solutions